Alligator Bioscience AB (ATORX) AI Stock Analysis

• Market Cap: kr140.09M
• Dividend Yield: N/A
• Average Volume (3M): 482.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.13
• Revenue Growth: -5.46%
• EPS Growth: N/A
• Country: SE
• Employees: 33
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 34,803,898
• 10 Day Avg. Volume: 672,228
• 30 Day Avg. Volume: 482,753
• PEG Ratio: 0.22
• Price to Book (P/B): -16.56
• Price to Sales (P/S): 37.43
• P/FCF Ratio: -10.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

Alligator Bioscience AB is facing severe financial and operational challenges. The company exhibits declining revenues, negative profit margins, and high leverage, significantly impacting its financial stability. Technical indicators also show a bearish trend, and valuation metrics are unfavorable due to negative earnings. Strategic changes are essential to improve its financial health and investor appeal.

Alligator Bioscience AB Business Overview & Revenue Model

Company Description

Alligator Bioscience AB (ATORX) is a biotechnology company specializing in the development of innovative antibody-based therapies for the treatment of cancer. The company focuses on developing next-generation immuno-oncology treatments that harness the body's immune system to combat cancer. Its core products include a pipeline of drug candidates designed to target specific immune pathways and enhance the body's ability to fight tumors.

How the Company Makes Money

Alligator Bioscience AB generates revenue primarily through strategic collaborations and licensing agreements with larger pharmaceutical companies. These partnerships often provide upfront payments, milestone payments upon reaching certain clinical or regulatory achievements, and royalties on future sales of successfully developed therapies. Additionally, the company may receive funding through government grants and research collaborations to support its R&D initiatives. The development and commercialization of its proprietary and partnered drug candidates are key drivers of its revenue model.

Alligator Bioscience AB Financial Statement Overview

Summary

Alligator Bioscience AB faces significant financial challenges. The income statement reveals persistent losses and declining revenues, while the balance sheet indicates high leverage and negative equity. Cash flow issues persist, with negative operating and free cash flows. The company needs strategic changes to improve profitability and financial stability.

Income Statement

The company shows declining revenue trends, with a significant drop in the most recent TTM period. Gross profit margins are negative, indicating cost issues. Net profit margins are also deeply negative, raising concerns about profitability. EBIT and EBITDA margins are both negative, reflecting operational challenges.

Balance Sheet

The company's balance sheet is highly leveraged with a negative stockholders' equity, posing financial stability risks. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, indicating insolvency issues. Return on equity is also negative due to sustained losses.

Cash Flow

Operating cash flow is negative, highlighting cash management challenges. Free cash flow is consistently negative, though recent financing activities have temporarily improved liquidity. The operating cash flow to net income ratio suggests operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	48.39M	57.77M	58.11M	35.70M	12.94M	4.35M
Gross Profit	48.39M	57.77M	58.11M	-112.03M	-74.04M	-77.97M
EBITDA	-53.09M	-165.47M	-237.61M	-180.99M	-130.39M	-131.46M
Net Income	-131.96M	-233.89M	-248.59M	-193.40M	-141.74M	-143.61M
Balance Sheet
Total Assets	86.23M	104.34M	118.45M	169.58M	333.20M	151.94M
Cash, Cash Equivalents and Short-Term Investments	33.90M	64.31M	66.12M	97.31M	278.15M	103.34M
Total Debt	39.55M	43.57M	16.10M	24.50M	9.74M	12.07M
Total Liabilities	120.96M	234.93M	106.59M	80.53M	50.93M	36.69M
Stockholders Equity	-34.73M	-130.59M	11.86M	89.05M	282.27M	115.24M
Cash Flow
Free Cash Flow	-162.69M	-212.43M	-191.74M	-173.05M	-127.08M	-141.45M
Operating Cash Flow	-161.23M	-212.43M	-189.28M	-172.61M	-127.03M	-141.35M
Investing Cash Flow	2.21M	0.00	-2.46M	-440.00K	-45.00K	156.89M
Financing Cash Flow	117.04M	211.27M	161.56M	-7.83M	301.80M	-6.15M

Alligator Bioscience AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Negative. The current price of 4.12 is below the 20-day moving average (MA) of 4.21, below the 50-day MA of 4.90, and below the 200-day MA of 18.65, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 45.52 is Neutral, neither overbought nor oversold. The STOCH value of 35.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ATORX.

Alligator Bioscience AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELIC	47 Neutral	251.90M	-11.87	0.00%	―	0.00%	53.88%
XINT	43 Neutral	286.12M	-6.66	0.00%	―	1192.39%	23.82%
EXPRS2	41 Neutral	45.78M	-0.85	-55.62%	―	-13.08%	32.78%
ATORX	39 Underperform	kr140.09M	―		―	-5.46%	―
BIOSGN	34 Underperform	111.54M	-3.94	0.00%	―	0.00%	65.16%
ACTI	32 Underperform	197.07M	-3.66	0.00%	―	0.00%	27.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%